Navigation Links
Stonegate Report About Unigene Laboratories Inc.
Date:3/13/2008

izes UGNE's manufacturing process. A positive outcome in either of these trials could catapult sCT to blockbuster status.

- UGNE's oral sCT program is progressing favorably - Apart from Novartis, Unigene is developing its own version of oral sCT utilizing tablets in an improved solid dosage form (patent applied for by the Company). The Company just announced the initiation of a Phase I/II trial, with dosing to be completed by the end of February 2008. Given the favorable market opportunities surrounding an oral sCT product, we anticipate the announcement of a partnership during the first half of 2008.

- Strong positive momentum - For the quarter ended September 30, 2007, revenues rose by 34% sequentially, reflecting a 71% increase in sales and royalties relating to Fortical(R). UGNE exhibited positive operating income for the third quarter and positive cash flow from operations for the nine months ended September 30, 2007. The cash balance grew significantly during the nine-month period, increasing by over $3.6 million to over $7 million.

- Valuation - With Fortical's imminent dominance in its market, an advancing pipeline targeting large markets, a dramatically improved financial position, and huge upside potential, we believe Unigene represents a compelling risk/reward opportunity.

Investment Summary

The commercialization of peptide-based therapeutics has been hindered by various technical challenges, and peptides have historically taken a backseat to small molecules as active pharmaceutical ingredients (APIs) for drug therapies. The advent of recombinant technology and recombinant protein production in therapeutics has facilitated the development of novel delivery systems and opened the door to new commercial opportunities for peptide-based therapies. According to Frost and Sullivan, peptides are poised to become "the products of the future", and the market for peptide-based active pharmaceutical ingredients is expected to grow
'/>"/>

SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Helix BioPharma reports Q2 2008 highlights, financial results
5. Oncothyreon reports full year and fourth quarter 2007 financial results
6. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... small package. For instance, these tiny cylinders of carbon ... than a metal conductor of the same size. It,s ... future nanoscale electronics. Butnot so fast. Recent tests ... suggest device reliability is a major issue. Copper ...
... Aug. 18, 2011 CBI is pleased to announce ... and Post-Approval Studies Congress, being held September 20-22, 2011 ... an impressive speaker lineup from Celgene, Covidien, FDA, Forest, ... more. Attendees have the opportunity to ...
... Creabilis SA, a clinical stage European biotechnology ... pain, announced today the expansion of its senior management ... executives. Alex Leech joins as Vice President, Head of ... Head of Development, and Peter Spargo as Senior Vice ...
Cached Biology Technology:NIST uncovers reliability issues for carbon nanotubes in future electronics 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2Creabilis Expands Senior Management Team 2Creabilis Expands Senior Management Team 3
(Date:7/11/2014)... from the Wildlife Conservation Society shows that no-take ... valuable species such as lobster, conch, and fish ... nearby reef areas. , The reporttitled "Review of ... of research literature from no-take areas around the ... Dahlgren, a recognized expert in marine protected areas ...
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... New South Wales, Australia when NASA,s Aqua satellite passed ... July 11 (12:35 p.m. local time/11:35 p.m. EDT on ... Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... spotted smoke (light brown) from various fires. Actively burning ... red. , The New South Wales, Australia Government website ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... Biosignal Ltd and the Institute for Eye Research have ... of an antibacterial extended-wear contact lens. , The ASX-listed ... researchers at the Centre for Marine Biofouling and Bioinnovation. ... compare the safety performance of an antibacterial contact lens ...
... sign of fragility. But in the case of infectious ... menacing pathogen. Howard Hughes Medical Institute researcher have discovered ... "seeds," which spread infection much more quickly. , The ... provide scientists with new ideas for designing drugs that ...
... child burns victims cope with the trauma of scarring, ... at the Royal Children's Hospital in Brisbane. , A ... the appearance of their scars and were happier when ... liquid spray-on skin technology, which binds to the topmost ...
Cached Biology News:First human trial of antibacterial contact lens 2Brittle prions are more infectious 2Brittle prions are more infectious 3
... hood is a component of ... on the transilluminator, it holds ... provides a darkroom environment that ... bench. This 13 x 17.8 ...
... Kit is a simple high performance method ... Removes detergents without significant dilution of protein ... on the Detergent-OUT Spin column and collect ... are suitable for removing detergent from a ...
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
Biology Products: